Home » Stocks » AMRX

Amneal Pharmaceuticals, Inc. (AMRX)

Stock Price: $5.20 USD -0.58 (-10.03%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $5.24 +0.04 (0.77%) May 7, 7:51 PM
Market Cap 771.82M
Revenue (ttm) 1.99B
Net Income (ttm) 91.06M
Shares Out 147.44M
EPS (ttm) 0.61
PE Ratio 8.52
Forward PE 8.04
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $5.20
Previous Close $5.78
Change ($) -0.58
Change (%) -10.03%
Day's Open 5.85
Day's Range 5.17 - 5.87
Day's Volume 2,387,368
52-Week Range 3.45 - 7.44

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Amneal (AMRX) delivered earnings and revenue surprises of 11.11% and -2.81%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

22 hours ago - Zacks Investment Research

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) announced its results today for the first quarter ended March 31, 2021. “Amneal delivered solid first quarte...

1 day ago - Business Wire

Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago - Zacks Investment Research

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its first quarter 2021 financial results on Friday, May 7, 2021, prior to mark...

3 weeks ago - Business Wire

NEW YORK, April 12, 2021 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty c...

3 weeks ago - PRNewsWire

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (the “Company”) (NYSE: AMRX) and Kashiv BioSciences LLC (“Kashiv”) today announced that Amneal Pharmaceuticals LLC (“Amneal”), a subsidia...

1 month ago - Business Wire

New York, New York--(Newsfile Corp. - March 31, 2021) - Levi & Korsinsky announces it has commenced an investigation of Amneal Pharmaceuticals, Inc. (NYSE: AMRX) concerning possible breaches of fiduciar...

1 month ago - Newsfile Corp

Investors who chase growth could be interested in the following small-cap stocks as they represent companies whose trailing 12-month net earnings per share improved significantly on a year-over-year basis.

Other stocks mentioned: CXP, JKS
1 month ago - GuruFocus

Amneal (AMRX) delivered earnings and revenue surprises of 7.69% and 1.55%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U...

2 months ago - Business Wire

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the "Company") announced its results today for the fourth quarter and full year ended December 31, 2020. "We are extremely ...

2 months ago - Business Wire

Amneal Pharmaceuticals (AMRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

2 months ago - Zacks Investment Research

BOSTON--(BUSINESS WIRE)--Company adds two directors with financial, pharmaceutical, and consumable business expertise.

Other stocks mentioned: MASS
2 months ago - Business Wire

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that its management team will virtually attend the following investor conferences: Raymond J...

2 months ago - Business Wire

AMRX vs. CORT: Which Stock Is the Better Value Option?

Other stocks mentioned: CORT
2 months ago - Zacks Investment Research

Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

2 months ago - Zacks Investment Research

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its fourth quarter and full year 2020 financial results on Friday, February 26...

3 months ago - Business Wire

AMRX vs. PCRX: Which Stock Is the Better Value Option?

Other stocks mentioned: PCRX
3 months ago - Zacks Investment Research

BeiGene (NASDAQ: BGNE) shares are trading higher after on Tuesday after the company announced a collaboration agreement with Novartis to developed and commercialize Anti-PD-1 antibody Tislelizumab. BeiG...

Other stocks mentioned: BGNE, TTOO
3 months ago - Benzinga

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (the “Company”) (NYSE:AMRX) and Kashiv BioSciences LLC (“Kashiv”) today announced they have entered into a definitive agreement under whi...

3 months ago - Business Wire

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced that it has received approval of an additional strength of 500 mg to its Abbreviated N...

3 months ago - Business Wire

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that Chirag Patel, Amneal's Co-Chief Executive Officer and President, will present at the 39...

4 months ago - Business Wire

As part of its outlook for biopharma companies in 2021, Guggenheim Securities turned bullish on Amneal Pharmaceuticals Inc (NYSE: AMRX). The Amneal Analyst: Dana Flanders upgraded Amneal from Neutral to...

4 months ago - Benzinga

These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q1 2021.

Other stocks mentioned: AMPH, BIIB, HZNP, PAHC, SUPN
5 months ago - Investopedia

Is Amneal Pharmaceuticals (AMRX) a great pick from the value investor's perspective right now? Read on to know more.

5 months ago - Zacks Investment Research

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal”) today announced that it has received approval for its Abbreviated New Drug Application (ANDA) from the U.S. Food ...

5 months ago - Business Wire

Amneal Pharmaceuticals, Inc. (AMRX) CEO Chintu Patel on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Shares of Amneal Pharmaceuticals (NYSE:AMRX) rose 1.0% in pre-market trading after the company reported Q3 results.

6 months ago - Benzinga

Amneal (AMRX) delivered earnings and revenue surprises of 23.08% and 8.13%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) announced its results today for the third quarter ended September 30, 2020. “Amneal delivered another strong...

6 months ago - Business Wire

Amneal (AMRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

6 months ago - Zacks Investment Research

Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

Amneal Pharmaceuticals (AMRX) closed at $4.36 in the latest trading session, marking a -1.13% move from the prior day.

6 months ago - Zacks Investment Research

Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

6 months ago - Zacks Investment Research

Is (AMRX) Outperforming Other Medical Stocks This Year?

6 months ago - Zacks Investment Research

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its third quarter 2020 financial results on Friday, November 6, 2020, prior to...

6 months ago - Business Wire

--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE:AMRX), headquartered in Bridgewater, NJ, is a fully-integrated pharmaceutical company focused on the development, manufacturing and distribution of ...

6 months ago - Business Wire

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal’ or the “Company”) and PL Developments (PLD) today announced that they have commenced shipments of store brand equi...

6 months ago - Business Wire

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc.

8 months ago - Business Wire

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc.

8 months ago - Business Wire

Amneal Pharmaceuticals, Inc. (AMRX) CEO Chintu Patel on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Amneal (AMRX) delivered earnings and revenue surprises of 30.00% and 3.73%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc.

9 months ago - Business Wire

Amneal (AMRX) will provide financial updates when it reports second-quarter 2020 results.

9 months ago - Zacks Investment Research

Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

In the latest trading session, Amneal Pharmaceuticals (AMRX) closed at $4.46, marking a +0.45% move from the previous day.

9 months ago - Zacks Investment Research

Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

9 months ago - Zacks Investment Research

Amneal Pharmaceuticals (AMRX) closed the most recent trading day at $4.86, moving +0.21% from the previous trading session.

9 months ago - Zacks Investment Research

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U...

9 months ago - Business Wire

Amneal Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

9 months ago - Zacks Investment Research

About AMRX

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates in three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the d... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
Founded
2002
Stock Exchange
NYSE
Ticker Symbol
AMRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 12 analysts, the average rating for AMRX stock is "Hold." The 12-month stock price forecast is 6.45, which is an increase of 24.04% from the latest price.

Price Target
$6.45
(24.04% upside)
Analyst Consensus: Hold